Sánchez-Sánchez LM, Edith del Ángel-Cruz E, Domínguez-Sansores LA

Language: Spanish
References: 18
Page: 197-201
PDF size: 30.89 Kb.

ABSTRACT

Mucopolysaccharidosis type I or mucopolisacaridosis type I is a rare genetic disease, with a severe and fast multiorganic damage profile and fatal prognosis in the early years of age. It belongs to the lysosomal storage diseases (LSD) group pathologies. As an LSD, mucopolisacaridosis type I is due to the lack of the α-L-iduronidase enzyme. Enzyme replacement therapy (ERT) with laronidase is an effective treatment choice. It is available in Mexico since 2005. In the Hospital UMAE 25 of the Mexican Institute of Social Security (IMSS) in Monterrey, Nuevo Leon, Mexico, three patients have been treated and followed since 2006, with a close surveillance on their clinical evolution. The ERT with laronidase is expensive, relatively new and with little experience in Mexico, so there is a real need of knowing clinical evolution as well as overall treatment efficacy from baseline pretreatment stage to date. Data on physical, functional and biochemical changes in these patients is presented.

REFERENCES

1. Wraith JE. Advances in the treatment of lysosomal storage disease. Dev Med Child Neurol 2003;43(9):639- 646.

2. Simonaro CM, D’Angelo M, Haskins ME, Schuchman EH. Bone and joint disease in the mucopolysaccharidosis. Am J Hum Genet 2003;73:449.

3. Brooks DA. Alpha-L-iduronidase and enzyme replacement theraphy for mucopolysaccharidosis I. Expert Opin Biol Ther 2002;2(8):967-976.

4. Kakkis ED. Enzyme replacement therapy for the mucopolysaccha- ride storage disorders. Expert Opin Invest Drugs 2002;11(5):675-685.

5. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M. Enzyme replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344(3):182-188. Disponible en http://www.nejm.org/doi/full/10.1056/NEJM20 0101183440304

6. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement theraphy for mucopolysaccharidosis I: a randomized, double blinded, placebo-controlled, multinational study or recombinant human alpha-L-Iduronidase (laronidasa). J Pediatr 2004; 144(5):581-588.

7. Neufeld EF, Muenzer J. The mucopolysaccharidosis. En: Scriver CR, Beaudet al, Sly WS, Valle D, editores. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3421-3452.

8. Wilcox WR. Lyposomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr 2004;144(Suppl 5):S3-S14.

9. Sá G, Teixeira J, Cruz R, Barbot C, Martins E. Aspectos neuroimagenológicos en la mucopolisacaridosis: correlación con el retraso mental. Rev Neurol 2006:43(12);760- 762.

10. Stephan MJ, Stevens EL Jr, Wenstrup RJ, Greenberg CR, Gritter HL, Hodges GF, et al. Mucopolysaccharidosis I presenting with endocardial fibroelastosis of infancy. Am J Dis Child 1989;143(7):782-784.

11. Van Meir N, De Smet L. Carpal tunnel sydrome in children. Acta Orthop Belg 2003;69(5):387-395.

12. Gilbert-Barness E. Metabolic cardiomyopathy and conduction system defects in children. Ann Clin Lab Sci 2004;34 (1):15-34.

13. Stephan MJ, Stevens EL Jr, Wenstrup RJ, Greenberg CR, Gritter HL, Hodges GF, et al. Mucopolysaccharidosis I presenting with endocardial fibroelastosis of infancy. Am J Dis Child 1989;143(7):782-784.

14. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 2004;144(Suppl 5):S27-S34.

15. Cohen SA. The important role of the pediatricians in recognizing clusters of symptoms in patinets with mucopolysaccharidosis I. San Francisco, USA: National Conference of the American Academy of Pediatrics; 2004.

16. Hall CW. Enzymatic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol 1978;50:439- 456.

17. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebocontrolled, multinational study of recombinant human a-L-Iduronidase (Laronidase). J Pediatr 2004;144(5):581- 588.

18. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 2004;144(Suppl 5):S27-S34.